Physician profile
Michael D Moore
NPI 1851140149
$926.11
in general payments reported to CMS, 2019-2025
21 companies · $766 in 2025
The $766 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $160 · 2025: $766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $926.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $331.86 | 2024-2025 | |
| Corcept Therapeutics | $73.25 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $57.60 | 2025 | |
| Novo Nordisk INC | $46.09 | 2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $45.99 | 2025 | Veozah |
| Pfizer INC. | $44.60 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $35.32 | 2025 | Airsupra |
| Gilead Sciences, INC. | $30.94 | 2025 | |
| Amgen INC. | $29.98 | 2025 | Krystexxa, Otezla, Repatha |
| Inspire Medical Systems, INC. | $23.33 | 2024 | Inspire |
| Hologic Sales and Service, LLC | $22.75 | 2025 | Thinprep 2000 Processor, Aptima |
| Glaxosmithkline, LLC. | $22.68 | 2025 | Trelegy Ellipta |
| Rgh Enterprises LLC | $19.96 | 2025 | |
| Indivior INC. | $19.92 | 2025 | Sublocade |
| Lilly USA, LLC | $19.49 | 2025 | Mounjaro |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $19.49 | 2025 | Azstarys |
| Alkermes, INC. | $19.33 | 2024 | Lybalvi |
| Exact Sciences Corporation | $16.72 | 2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $16.29 | 2025 | Auvelity |
| Braeburn INC. | $16.27 | 2024 | Brixadi |
| Kowa Pharmaceuticals America, INC. | $14.25 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.